ArticleThe oncologist2021

A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors.

Hui K Gan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.